XML 98 R81.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Oct. 01, 2017
Oct. 02, 2016
Oct. 01, 2017
Oct. 02, 2016
Revenue from External Customer [Line Items]        
Revenues [1] $ 13,168 $ 13,045 $ 38,843 $ 39,196
Innovative Health and Essential Health [Member]        
Revenue from External Customer [Line Items]        
Revenues 13,168 13,045 38,843 39,196
Innovative Health and Essential Health [Member] | Lyrica [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 1,285 1,240 3,810 3,730
Innovative Health and Essential Health [Member] | Viagra [Member]        
Revenue from External Customer [Line Items]        
Revenues [3] 308 387 996 1,183
Innovative Health and Essential Health [Member] | Alliance revenues [Member]        
Revenue from External Customer [Line Items]        
Revenues 741 419 2,112 1,155
Innovative Health Business [Member] | IH [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 8,118 7,332 23,204 21,471
Essential Health Business [Member] | EH [Member]        
Revenue from External Customer [Line Items]        
Revenues [5] 5,050 5,712 15,639 17,725
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member]        
Revenue from External Customer [Line Items]        
Revenues [6] 2,681 2,708 7,995 8,373
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member]        
Revenue from External Customer [Line Items]        
Revenues 491 422 1,341 1,294
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member]        
Revenue from External Customer [Line Items]        
Revenues 238 244 711 751
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member]        
Revenue from External Customer [Line Items]        
Revenues 226 238 684 714
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | EpiPen [Member]        
Revenue from External Customer [Line Items]        
Revenues 82 110 253 300
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xalatan/Xalacom [Member]        
Revenue from External Customer [Line Items]        
Revenues 83 91 241 273
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member]        
Revenue from External Customer [Line Items]        
Revenues 76 70 215 207
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member]        
Revenue from External Customer [Line Items]        
Revenues 78 72 215 228
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zithromax [Member]        
Revenue from External Customer [Line Items]        
Revenues 61 56 202 203
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Relpax [Member]        
Revenue from External Customer [Line Items]        
Revenues 50 83 193 248
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xanax [Member]        
Revenue from External Customer [Line Items]        
Revenues 58 55 164 163
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,237 1,268 3,776 3,992
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member]        
Revenue from External Customer [Line Items]        
Revenues [7] 1,273 1,461 4,270 4,481
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member]        
Revenue from External Customer [Line Items]        
Revenues 109 102 352 330
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member]        
Revenue from External Customer [Line Items]        
Revenues 114 102 345 304
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member]        
Revenue from External Customer [Line Items]        
Revenues 79 80 221 240
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member]        
Revenue from External Customer [Line Items]        
Revenues 60 69 192 203
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member]        
Revenue from External Customer [Line Items]        
Revenues 51 64 182 199
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member]        
Revenue from External Customer [Line Items]        
Revenues 860 1,044 2,977 3,206
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member]        
Revenue from External Customer [Line Items]        
Revenues [8] 794 1,023 2,398 3,224
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 134 191 428 623
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member]        
Revenue from External Customer [Line Items]        
Revenues [3] 102 89 285 286
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member]        
Revenue from External Customer [Line Items]        
Revenues 212 194 564 550
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member]        
Revenue from External Customer [Line Items]        
Revenues 97 140 305 459
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member]        
Revenue from External Customer [Line Items]        
Revenues 69 174 230 546
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member]        
Revenue from External Customer [Line Items]        
Revenues 68 94 220 334
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member]        
Revenue from External Customer [Line Items]        
Revenues 58 73 189 213
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member]        
Revenue from External Customer [Line Items]        
Revenues 55 68 176 214
Biosimilars [Member] | Essential Health Business [Member] | EH [Member]        
Revenue from External Customer [Line Items]        
Revenues [9] 141 83 367 228
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member]        
Revenue from External Customer [Line Items]        
Revenues 112 49 284 130
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member]        
Revenue from External Customer [Line Items]        
Revenues 28 34 82 97
CentreOne [Member] | Essential Health Business [Member] | EH [Member]        
Revenue from External Customer [Line Items]        
Revenues [10] 161 156 514 540
Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member]        
Revenue from External Customer [Line Items]        
Revenues [11] 0 281 97 879
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member]        
Revenue from External Customer [Line Items]        
Revenues 2,455 2,243 7,245 6,557
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 1,150 1,049 3,382 3,107
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member]        
Revenue from External Customer [Line Items]        
Revenues 644 449 1,813 1,225
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member]        
Revenue from External Customer [Line Items]        
Revenues 240 198 727 631
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member]        
Revenue from External Customer [Line Items]        
Revenues [3] 206 297 711 897
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member]        
Revenue from External Customer [Line Items]        
Revenues 79 63 198 175
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member]        
Revenue from External Customer [Line Items]        
Revenues 62 60 187 191
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member]        
Revenue from External Customer [Line Items]        
Revenues 75 128 228 330
Vaccines [Member] | Innovative Health Business [Member] | IH [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,649 1,641 4,385 4,576
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevnar 13/Prevenar 13 [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,522 1,536 4,069 4,302
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member]        
Revenue from External Customer [Line Items]        
Revenues 43 33 119 102
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member]        
Revenue from External Customer [Line Items]        
Revenues 85 72 197 172
Oncology [Member] | Innovative Health Business [Member] | IH [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,616 1,104 4,551 3,206
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member]        
Revenue from External Customer [Line Items]        
Revenues 878 550 2,410 1,492
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member]        
Revenue from External Customer [Line Items]        
Revenues 276 260 805 823
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member]        
Revenue from External Customer [Line Items]        
Revenues 146 140 442 415
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member]        
Revenue from External Customer [Line Items]        
Revenues 150 2 422 2
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member]        
Revenue from External Customer [Line Items]        
Revenues 84 95 256 304
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Bosulif [Member]        
Revenue from External Customer [Line Items]        
Revenues 57 43 163 121
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member]        
Revenue from External Customer [Line Items]        
Revenues 26 15 54 49
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,000 960 2,863 2,907
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member]        
Revenue from External Customer [Line Items]        
Revenues 613 701 1,818 2,201
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member]        
Revenue from External Customer [Line Items]        
Revenues 348 235 935 649
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member]        
Revenue from External Customer [Line Items]        
Revenues 15 0 33 0
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member]        
Revenue from External Customer [Line Items]        
Revenues 23 24 78 57
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member]        
Revenue from External Customer [Line Items]        
Revenues 569 585 1,637 1,768
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member]        
Revenue from External Customer [Line Items]        
Revenues 151 176 453 543
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member]        
Revenue from External Customer [Line Items]        
Revenues 140 140 409 408
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member]        
Revenue from External Customer [Line Items]        
Revenues 136 147 375 425
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member]        
Revenue from External Customer [Line Items]        
Revenues 65 59 182 173
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member]        
Revenue from External Customer [Line Items]        
Revenues 77 64 218 219
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member]        
Revenue from External Customer [Line Items]        
Revenues $ 829 $ 798 $ 2,522 $ 2,457
[1] Amounts may not add due to rounding.
[2] Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3] Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[4] The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.
[5] The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.
[6] Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above.
[7] Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).
[8] Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra.
[9] Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
[10] Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis.
[11] HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.